“Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% against mild, moderate, and severe Covid-19 disease. The efficacy against severe Covid-19 disease was 100%, with an impact on reduction in hospitalisations. The efficacy against asymptomatic Covid-19 infection was 70%, suggesting decreased transmission in Covaxin recipients,” they said in a joint statement.
The Covaxin developers said that the safety and efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
Prof Balram Bhargava, secretary to the department of Health Research and Director General, Indian Council of Medical Research, said: “The tireless efforts of our scientists at ICMR and BBIL have resulted in a truly effective international vaccine of the highest standards and efficacy. I am also happy to note that Covaxin works well against most variants of SARS
“Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% against mild, moderate, and severe Covid-19 disease. The efficacy against severe Covid-19 disease was 100%, with an impact on reduction in hospitalisations. The efficacy against asymptomatic Covid-19 infection was 70%, suggesting decreased transmission in Covaxin recipients,” they said in a joint statement.
The Covaxin developers said that the safety and efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
Prof Balram Bhargava, secretary to the department of Health Research and Director General, Indian Council of Medical Research, said: “The tireless efforts of our scientists at ICMR and BBIL have resulted in a truly effective international vaccine of the highest standards and efficacy. I am also happy to note that Covaxin works well against most variants of SARS
Bharat Biotech Covaxin Demonstrates 78 Percent Efficacy In Treating Covid-19 Apr 21, 2021, 19:56 IST
The efficacy against severe COVID-19 disease was 100 per cent with an impact on reduction in hospitalizations.
The efficacy against asymptomatic COVID-19 infection was 70 per cent, suggesting decreased transmission in Covaxin recipients, it said.
HYDERABAD: Bharat Biotech-developed Covaxin demonstrated 78 percent efficacy in treating COVID-19 as per reports released by the company.
In a press release, the company stated that the overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19as per the phase 3 interim analysis results of the vaccine.
The efficacy against severe COVID-19 disease was 100 per cent with an impact on reduction in hospitalizations.